1
|
Cummiskey AG, Byrne A, Spencer M, Whelan M, Nee R. 108 TEIRIPE SA BHAILE TEAM (TSAB): AN EARLY SUPPORTED DISCHARGE SERVICE FOR HIP FRACTURES FROM AN ACUTE HOSPITAL. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Due to increasing bed strain in hospitals, Early Supported Discharge (ESD) programmes have helped to reduce length of stay for hip fracture patients. Teiripe sa Bhaile Team (TsaB) provides a multi-disciplinary, patient centred approach to care for patients over 60 with hip fractures, in their own home.
Methods
Patient demographics and data has been collected on all TsaB patients to date with consent from the patients. We measured length of intervention with TsaB, patient directed SMART (Specific, measurable, achievable, relevant, time bound) goals, Functional Independence Measure (FIM) sores. We recorded the number of visits required, medical complications and number of readmissions post discharge from our service.
Results
Since formation in 2018 until April 2022, 33 patients have been treated by TsaB. The average age is 78 years old. The average length of stay prior to discharge was 17 days, compared to 54 days for inpatient hip fracture rehabilitation. Patients received an average of 11 MDT visits during the 6 weeks of rehabilitation. The average improvement in FIM score was 42. All set SMART goals, and only 5 (17%) patients did not achieve these goals.
Only 5 (17%) patients were readmitted within 6 months. No patients required initiation of a home care package for discharge, or after our interventions. No patients developed pressure ulcers while on our service, or other medical complications.
Conclusion
Through TsaB, we are able to offer a rehabilitation service to patients based around their own needs in the home. Patients were able to set and achieve their own SMART goals. Patients were moderately frail on admission to our service, but after intervention were able to improve their FIM scores, marking reduced frailty after intervention. We had low readmission rates, and no patients required a change in home care package.
Collapse
Affiliation(s)
| | - A Byrne
- St. James Hospital , Dublin, Ireland
| | - M Spencer
- St. James Hospital , Dublin, Ireland
| | - M Whelan
- St. James Hospital , Dublin, Ireland
| | - R Nee
- St. James Hospital , Dublin, Ireland
| |
Collapse
|
2
|
Bradley E, Byrne A, Ramalingam K, Mills D, Spencer M, Wheelan M, Nee R. 318 CARER STRESS REVIEW IN COMPLEX CASES REQUIRING INTERVENTION BY A COMMUNITY-BASED OLDER PERSONS TEAM. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Complex cases of older adults suffering from multimorbidity are continuing to increase in number. The integrated care team, overseen by a consultant geriatrician, aims to facilitate the management of stable complex cases in the community. Patient care is largely affected by their support system at home; therefore, it is of great importance to ensure that the patient’s primary carer is receiving the support they require to facilitate the older patients’ management in the community. Our aim is to assess carer stress levels before and after Multi-Disciplinary Team (MDT) integrated care intervention.
Methods
Study Population were carers of patients identified as complex cases by the integrated care team. Caregiver stress index was administered during the initial assessment and on the closing of active cases. The maximum score on this index is 13 with high stress classified as >7. Scores were added to a spreadsheet. This spreadsheet was reviewed, and relevant data was collated. One year assessed March 2021- March 2022.
Results
Carer stress information was collected on 62 of 112 identified complex cases (55%). Of these 55 of 96 individual patients were represented (57%). Average age 82 years old. 65% female and 35%, male. Range of carer stress scores observed 0- to 12. Of the 62 cases, 85% (53 cases) had a reduction in carer stress post-intervention(p<0.01). Of these 65% had a reduction below 7 (p<0.01). Mean score improvement 7. No carer stress indices disimproved post-treatment.
Conclusion
Multidisciplinary, patient-centred community care has a clear positive impact on the patient carer. Improvements in carer stress scores could be further evaluated as to the benefits of specific interventions in time. In future, a more large-scale collection and interpretation of data would need to occur for a more conclusive positive impact of the community based integrated care team to be confirmed.
Collapse
Affiliation(s)
- E Bradley
- St. James Hospital , Dublin, Ireland
| | | | | | | | | | | | - R Nee
- St. James Hospital , Dublin, Ireland
| |
Collapse
|
3
|
Bradley E, Mills D, Byrne A, Ramalingam K, Spencer M, Wheelan M, Nee R. 314 COMMUNITY-BASED INTEGRATED CARE TEAMS EFFECTIVENESS IN PREVENTING CRISIS EMERGENCY DEPARTMENT ATTENDANCES. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Community based integrated care Multi-Disciplinary Teams (MDT) are a mainstay for future management of older adults. They have evolved to meet the needs of many different sub-types of clinical cases in the community. Complex Cases, are patients over 65 who reside within the catchment area, suffer from at least 2 frailty traits, and would be at increased risk of crisis emergency department (ED) attendance. Can the crisis ED attendances be prevented by integrated care team intervention?
Methods
The study population comprised adults identified as complex cases as per integrated care team standard operating procedure. Collated data was reviewed, and electronic medical records assessed as to whether any complex cases had been admitted within 30 days, 60 days, and 1 year of community team review. The study time frame was March 2021- to March 2022. As many patients have more than one unique identifying number, all patients were double-checked with an assessment based on their name and date of birth.
Results
112 complex cases were identified within one year, and 96 individual patients were represented. Average age 83 years old. 65% female and 35% male. 11% were admitted to hospital within 30 days, a further 6% were admitted within 60 days and by one year 30% of reviewed complex cases had been admitted to hospital.
Conclusion
In one year 70% of complex cases have been successfully maintained in the community. This has been achieved based on a multidisciplinary-based, patient-centred care approach. Given that 53% of hospital inpatient bed days are occupied by those over 65. This review concurs with previous research suggesting that an increase in community based integrated care teams is justified and should the aim for a fully staffed team per 150,000 patients over 65 come to fruition more than two-thirds of even the most complicated geriatric cases could be managed in the community.
Collapse
Affiliation(s)
- E Bradley
- St. James Hospital , Dublin, Ireland
| | | | - A Byrne
- Meath Primary Care Centre , Dublin, Ireland
| | | | | | | | - R Nee
- St. James Hospital , Dublin, Ireland
| |
Collapse
|
4
|
Perera N, Douglas D, Maddox M, Spencer M, Rodriguez L, Clinton J, Shu W. P05-04 hTERT immortalized neonatal melanocytes – an advanced in vitro cell based model for pigmentation and toxicity studies. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Affiliation(s)
- D. Ferraretto
- School of GeoSciences University of Edinburgh Crew Building Edinburgh EH9 3FF UK
| | - R. Nair
- Department Biogeochemical Integration Max Planck Institute for Biogeochemistry Jena Germany
| | - N. W. Shah
- Forest Research Northern Research Station Roslin Midlothian EH25 9SY UK
| | - D. Reay
- School of GeoSciences University of Edinburgh Crew Building Edinburgh EH9 3FF UK
| | - M. Mencuccini
- CREAF Bellaterra (Cerdanyola del Vallès) 08193 Spain
- ICREA Pg. Lluís Companys 23 Barcelona 08010 Spain
| | - M. Spencer
- School of GeoSciences University of Edinburgh Crew Building Edinburgh EH9 3FF UK
| | - K. V. Heal
- School of GeoSciences University of Edinburgh Crew Building Edinburgh EH9 3FF UK
| |
Collapse
|
6
|
Lovegrove C, Spencer M, Turney B, Neal N. 327 Relative Benefits of Extracorporeal Shockwave Lithotripsy (ESWL) Compared to Observation in Acute Renal Colic. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Aim
NICE guidance recommends patients with renal colic be offered surgical treatment, including extracorporeal shockwave lithotripsy (ESWL), within 48 hours if pain is uncontrolled or stones unlikely to pass. We compared outcomes for ureteric stone passage after ESWL with those of observation to ascertain the relative benefits of ESWL.
Method
We collected data on stone location, size, and number of ESWL treatments required prospectively over 18 months. Stone passage was confirmed radiologically. Data were compared with MIMIC, a multi-centre collaborative study examining spontaneous stone passage after observation alone.
Results
166 patients had ESWL for ureteric stones. Median size was 6.5mm (IQR 5.0-8.0mm). 57.2% (N = 95) were proximal stones. Smaller stones required fewer treatments (P = 0.003). Patients with a ureteric stone <5mm required median 1.0 ESWL treatments (IQR 1.0-2.0). Ureteric stones 5-7mm had median 1.0 treatments (IQR 1.0-2.0) and stones >7mm median 2.0 treatments (IQR 1.0-2.0). Compared to MIMIC, patients with ESWL for stones <5mm were 11% more likely to achieve stone clearance (100.0% vs 89.0%, P = 0.001). ESWL for 5-7mm stones had 28.1% greater clearance compared to observation (77.1% vs. 49.0%, P < 0.001) and ESWL for stones >7mm 21% greater likelihood of clearance (50.0% vs. 29.0%, P < 0.001). Proximal ureteric stones were 16.4% more likely to pass with ESWL than observation (68.4% vs 52%, P = 0.02). Distal stones showed similar passage with ESWL (77.5%) and observation (83.0%), P = 0.43.
Conclusions
Proximal ureteric stones and those >5mm stones benefit most from ESWL. Results aid identification of patients whose stones are less likely to pass and warrant urgent review to consider ESWL.
Collapse
Affiliation(s)
- C Lovegrove
- Oxford University Hospitals NHS Trust, Oxford, United Kingdom
- University of Oxford Nuffield Department of Surgical Sciences, Oxford, United Kingdom
| | - M Spencer
- Oxford University Hospitals NHS Trust, Oxford, United Kingdom
| | - B Turney
- Oxford University Hospitals NHS Trust, Oxford, United Kingdom
- University of Oxford Nuffield Department of Surgical Sciences, Oxford, United Kingdom
| | - N Neal
- Oxford University Hospitals NHS Trust, Oxford, United Kingdom
| |
Collapse
|
7
|
Perera N, Spencer M, Rodriguez L, Huuskonen J. An in vitro Cell Model for Toxicity Studies and Pigmentation Regulation Utilizing hTERT Immortalized Neonatal Dermal Melanocytes. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00502-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Morikane K, Russo PL, Lee KY, Chakravarthy M, Ling ML, Saguil E, Spencer M, Danker W, Seno A, Charles EE. Expert commentary on the challenges and opportunities for surgical site infection prevention through implementation of evidence-based guidelines in the Asia-Pacific Region. Antimicrob Resist Infect Control 2021; 10:65. [PMID: 33795007 PMCID: PMC8017777 DOI: 10.1186/s13756-021-00916-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 02/26/2021] [Indexed: 02/07/2023] Open
Abstract
INTRODUCTION Surgical site infections (SSIs) are a significant source of morbidity and mortality in the Asia-Pacific region (APAC), adversely impacting patient quality of life, fiscal productivity and placing a major economic burden on the country's healthcare system. This commentary reports the findings of a two-day meeting that was held in Singapore on July 30-31, 2019, where a series of consensus recommendations were developed by an expert panel composed of infection control, surgical and quality experts from APAC nations in an effort to develop an evidence-based pathway to improving surgical patient outcomes in APAC. METHODS The expert panel conducted a literature review targeting four sentinel areas within the APAC region: national and societal guidelines, implementation strategies, postoperative surveillance and clinical outcomes. The panel formulated a series of key questions regarding APAC-specific challenges and opportunities for SSI prevention. RESULTS The expert panel identified several challenges for mitigating SSIs in APAC; (a) constraints on human resources, (b) lack of adequate policies and procedures, (c) lack of a strong safety culture, (d) limitation in funding resources, (e) environmental and geographic challenges, (f) cultural diversity, (g) poor patient awareness and (h) limitation in self-responsibility. Corrective strategies for guideline implementation in APAC were proposed that included: (a) institutional ownership of infection prevention strategies, (b) perform baseline assessments, (c) review evidence-based practices within the local context, (d) develop a plan for guideline implementation, (e) assess outcome and stakeholder feedback, and (f) ensure long-term sustainability. CONCLUSIONS Reducing the risk of SSIs in APAC region will require: (a) ongoing consultation and collaboration among stakeholders with a high level of clinical staff engagement and (b) a strong institutional and national commitment to alleviate the burden of SSIs by embracing a safety culture and accountability.
Collapse
Affiliation(s)
- K Morikane
- Division of Clinical Laboratory and Infection Control, Yamagata University Hospital, Yamagata, Japan
| | - P L Russo
- School of Nursing and Midwifery, Monash University, Frankston, VC, Australia
| | - K Y Lee
- Department of Surgery, KyungHee University Medical Center, Seoul, South Korea
| | | | - M L Ling
- Infection Prevention and Epidemiology, Singapore General Hospital, Singapore, Singapore
| | - E Saguil
- Philippine General Hospital, Manila, Philippines
| | - M Spencer
- Infection Prevention Consultant, Boston, MA, USA
| | - W Danker
- Ethicon, Johnson and Johnson Medical Device Companies, Somerville, NJ, USA
| | - A Seno
- Johnson and Johnson Medical Asia Pacific, Singapore, Singapore
| | - E Edmiston Charles
- Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
| |
Collapse
|
9
|
Wein N, Simmons T, Rajakumar D, Lesman D, Li D, Gaffney C, Rafferty R, Huang N, Rodriguez Y, Young C, Spencer M, Flanigan K. DMD – ANIMAL MODELS & PRECLINICAL TREATMENT. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Levy J, Boslego J, Wrubel M, Wrubel L, Spencer M. REGISTRIES, CARE, QUALITY OF LIFE, MANAGEMENT OF NMD. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
González-Mera L, Ravenscroft G, Cabrera-Serrano M, Ermolova N, Domínguez-González C, Arteche-López A, Soltanzadeh P, Evesson F, Navas C, Mavillard F, Clayton J, Rodrigo P, Servián-Morilla E, Cooper ST, Waddell L, Reardon K, Corbett A, Hernandez-Laín A, Sanchez A, Esteban Perez J, Paradas-Lopez C, Rivas-Infante E, Spencer M, Laing N, Olivé M. Heterozygous CAPN3 missense variants causing autosomal-dominant calpainopathy in seven unrelated families. Neuropathol Appl Neurobiol 2020; 47:283-296. [PMID: 32896923 DOI: 10.1111/nan.12663] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 08/03/2020] [Accepted: 08/22/2020] [Indexed: 01/05/2023]
Abstract
AIMS Recessive variants in CAPN3 gene are the cause of the commonest form of autosomal recessive limb girdle muscle dystrophy. However, two distinct in-frame deletions in CAPN3 (NM_000070.3:c.643_663del21 and c.598_621del15) and more recently, Gly445Arg and Arg572Pro substitutions have been linked to autosomal dominant (AD) forms of calpainopathy. We report 21 affected individuals from seven unrelated families presenting with an autosomal dominant form of muscular dystrophy associated with five different heterozygous missense variants in CAPN. METHODS We have used massively parallel gene sequencing (MPS) to determine the genetic basis of a dominant form of limb girdle muscular dystrophy in affected individuals from seven unrelated families. RESULTS The c.700G> A, [p.(Gly234Arg)], c.1327T> C [p.(Ser443Pro], c.1333G> A [p.(Gly445Arg)], c.1661A> C [p.(Tyr554Ser)] and c.1706T> C [p.(Phe569Ser)] CAPN3 variants were identified. Affected individuals presented in young adulthood with progressive proximal and axial weakness, waddling walking and scapular winging or with isolated hyperCKaemia. Muscle imaging showed fatty replacement of paraspinal muscles, variable degrees of involvement of the gluteal muscles, and the posterior compartment of the thigh and minor changes at the mid-leg level. Muscle biopsies revealed mild myopathic changes. Western blot analysis revealed a clear reduction in calpain 3 in skeletal muscle relative to controls. Protein modelling of these variants on the predicted structure of calpain 3 revealed that all variants are located in proximity to the calmodulin-binding site and are predicted to interfere with proteolytic activation. CONCLUSIONS We expand the genotypic spectrum of CAPN3-associated muscular dystrophy due to autosomal dominant missense variants.
Collapse
Affiliation(s)
- L González-Mera
- Neuropathology Unit, Department of Pathology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.,Neuromuscular Unit, Department of Neurology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - G Ravenscroft
- Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, WA, Australia
| | - M Cabrera-Serrano
- Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, WA, Australia.,Neurology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocıo/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - N Ermolova
- Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - C Domínguez-González
- Neuromuscular Unit, Department of Neurology, Hospital Universitario 12 de Octubre, Research Institute imas12, Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - A Arteche-López
- Department of Genetic, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Soltanzadeh
- Departments of Neurology and Physiology, David Geffen School of Medicine, UCLA, University of California, Los Angeles, CA, USA
| | - F Evesson
- Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, NSW, Australia.,The Children's Medical Research Institute, Westmead, NSW, Australia
| | - C Navas
- Neuropathology Unit, Department of Pathology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - F Mavillard
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocıo/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - J Clayton
- Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, WA, Australia
| | - P Rodrigo
- Neuropathology Unit, Department of Pathology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.,Neuromuscular Unit, Department of Neurology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - E Servián-Morilla
- Neurology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocıo/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - S T Cooper
- Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, NSW, Australia.,The Children's Medical Research Institute, Westmead, NSW, Australia.,Discipline of Child and Adolescent Health, Faculty of Health and Medicine, University of Sydney, Westmead, NSW, Australia
| | - L Waddell
- Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, NSW, Australia.,Discipline of Child and Adolescent Health, Faculty of Health and Medicine, University of Sydney, Westmead, NSW, Australia
| | - K Reardon
- St. Vincent's Melbourne Neuromuscular Diagnostic Laboratory, Department of Clinical Neurosciences and Neurological Research, St Vincent's Hospital, Melbourne, VIC, Australia
| | - A Corbett
- Department of Neurology, Concord General Repatriation Hospital, Sydney, NSW, Australia
| | - A Hernandez-Laín
- Department of Pathology, Neuropathology Unit. Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Sanchez
- Institut de Diagnòstic per la imatge (IDI), IDIBELL-Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - J Esteban Perez
- Neuromuscular Unit, Department of Neurology, Hospital Universitario 12 de Octubre, Research Institute imas12, Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - C Paradas-Lopez
- Neurology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocıo/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - E Rivas-Infante
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.,Department of Neuropathology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
| | - M Spencer
- Department of Neurology, Neuromuscular Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - N Laing
- Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, WA, Australia
| | - M Olivé
- Neuropathology Unit, Department of Pathology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.,Neuromuscular Unit, Department of Neurology, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
12
|
Gnant M, Martin M, Holmes FA, Jackisch C, Chia SK, Iwata H, Moy B, Martinez N, Mansi J, Morales S, Ruiz-Borrego M, von Minckwitz G, Buyse M, Delaloge S, Bhandari M, Murias Rosales A, Galeano T, Fujita T, Luczak A, Barrios CH, Saura C, Rugo HS, Chien J, Johnston SR, Spencer M, Xu F, Barnett B, Chan A, Ejlertsen B. Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-13-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that 1 year (yr) of neratinib 240 mg/day after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in 2840 patients with early-stage HER2+ breast cancer at 2 yr (hazard ratio 0.67; 95% CI 0.50–0.91; p=0.009) [Chan 2016] and 5 yr (hazard ratio 0.73; 95% CI 0.57-0.92; p=0.008) [Martin 2017]. A prespecified subgroup analysis by hormone receptor (HR) status suggested enhanced efficacy with neratinib in patients with HR+ (2-yr hazard ratio 0.51; 95% CI 0.33–0.77) vs. HR– tumors (2-yr hazard ratio 0.93; 95% CI 0.60–1.43). The efficacy of neratinib was also greater in patients who initiated treatment within 1 yr of prior trastuzumab compared with those who started neratinib later. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended neratinib for use in patients with HR+ tumors who initiate treatment within 1 yr of completing trastuzumab-based adjuvant therapy. Subgroup analyses from ExteNET examining iDFS benefits in this patient population are presented here.
Methods: Patients with early-stage HER2+ breast cancer who completed trastuzumab-based (neo)adjuvant therapy were assigned to oral neratinib 240 mg/day or placebo for 1 yr. Randomization was stratified by HR status (determined locally before trial entry), nodal status, and trastuzumab regimen. Endocrine therapy was allowed in patients with HR+ disease. The primary endpoint, iDFS, was tested by 2-sided log-rank test and hazard ratios (95% CI) were estimated using Cox proportional hazards models. Kaplan-Meier methods were used to estimate iDFS rates. Secondary endpoints were DFS-DCIS, time to distant recurrence, distant DFS, and CNS recurrences. The primary analysis was conducted at 2 yr, and a sensitivity analysis conducted at 5 yr. Clinicaltrials.gov:NCT00878709.
Results: Of the 2840 patients (neratinib, n=1420; placebo, n=1420), 1631 (57%) had HR+ disease (neratinib, n=816; placebo, n=815). Most (93%) HR+ patients were receiving endocrine therapy at baseline. 1334 of 1631 (82%) patients with HR+ tumors were randomized to start neratinib within 1 yr of last trastuzumab dose (neratinib, n=670; placebo, n=664). iDFS benefits from neratinib in this population are shown in the table. Secondary endpoints were also improved with neratinib vs. placebo in this population. Safety data in this subset will be presented at the meeting.
Table. iDFS in patients with an interval between last trastuzumab dose and randomization of ≤1 yr
HR+ population (N=1334)ITT population (N=2297) Hazard ratiob Hazard ratiob Δ, %a(95% CI)P-valueΔ, %a(95% CI)P-value2-yr analysisc+4.50.490.002+2.90.630.006 (0.30–0.78) (0.45–0.88) 5-yr analysisd+5.10.580.002+3.20.700.006 (0.41–0.82) (0.54–0.90) aDifference in iDFS rates between neratinib vs. placebo; bNeratinib vs. placebo; cData cut-off: July 2014; dData cut-off: March 2017
Conclusions: Neratinib may have enhanced and sustained efficacy in patients with HR+ disease who initiate treatment within 1 yr of trastuzumab-based adjuvant therapy.
Citation Format: Gnant M, Martin M, Holmes F-A, Jackisch C, Chia SK, Iwata H, Moy B, Martinez N, Mansi J, Morales S, Ruiz-Borrego M, von Minckwitz G, Buyse M, Delaloge S, Bhandari M, Murias Rosales A, Galeano T, Fujita T, Luczak A, Barrios CH, Saura C, Rugo HS, Chien J, Johnston SR, Spencer M, Xu F, Barnett B, Chan A, Ejlertsen B. Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-13-01.
Collapse
Affiliation(s)
- M Gnant
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - M Martin
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - F-A Holmes
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - C Jackisch
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - SK Chia
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - H Iwata
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - B Moy
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - N Martinez
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - J Mansi
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - S Morales
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - M Ruiz-Borrego
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - G von Minckwitz
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - M Buyse
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - S Delaloge
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - M Bhandari
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - A Murias Rosales
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - T Galeano
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - T Fujita
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - A Luczak
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - CH Barrios
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - C Saura
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - HS Rugo
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - J Chien
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - SR Johnston
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - M Spencer
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - F Xu
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - B Barnett
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - A Chan
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| | - B Ejlertsen
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catan
| |
Collapse
|
13
|
Lu N, Spencer M, Lou VWQ. WHAT MATTERS FOR LIFE SATISFACTION AMONG DISABLED OLDER ADULTS WHO LIVE ALONE IN URBAN CHINA: FAMILIES OR COMMUNITIES? Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- N Lu
- Department of Social Work, Renmin University of China, Haidian District, Beijing, China (People’s Republic)
| | - M Spencer
- Faculty of Education and Social Work, The University of Sydney, Australia
| | - V W Q Lou
- Department of Social Work & Social Administration, Sau Po Centre on Ageing, The University of Hong Kong
| |
Collapse
|
14
|
Sepúlveda-Hermosilla G, Blanco A, Lizana R, Ramos L, Freire M, Spencer M, Chernilo S, Aren O, Perez P, Armisen R. PD.1.05 Molecular Characterization of EGFR Somatic Mutations in Lung Adenocarcinoma Tumors from Chilean Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Tang WW, McGee P, Lachin JM, Li DY, Hoogwerf B, Hazen SL, Nathan D, Zinman B, Crofford O, Genuth S, Brown‐Friday J, Crandall J, Engel H, Engel S, Martinez H, Phillips M, Reid M, Shamoon H, Sheindlin J, Gubitosi‐Klug R, Mayer L, Pendegast S, Zegarra H, Miller D, Singerman L, Smith‐Brewer S, Novak M, Quin J, Genuth S, Palmert M, Brown E, McConnell J, Pugsley P, Crawford P, Dahms W, Gregory N, Lackaye M, Kiss S, Chan R, Orlin A, Rubin M, Brillon D, Reppucci V, Lee T, Heinemann M, Chang S, Levy B, Jovanovic L, Richardson M, Bosco B, Dwoskin A, Hanna R, Barron S, Campbell R, Bhan A, Kruger D, Jones J, Edwards P, Bhan A, Carey J, Angus E, Thomas A, Galprin A, McLellan M, Whitehouse F, Bergenstal R, Johnson M, Gunyou K, Thomas L, Laechelt J, Hollander P, Spencer M, Kendall D, Cuddihy R, Callahan P, List S, Gott J, Rude N, Olson B, Franz M, Castle G, Birk R, Nelson J, Freking D, Gill L, Mestrezat W, Etzwiler D, Morgan K, Aiello L, Golden E, Arrigg P, Asuquo V, Beaser R, Bestourous L, Cavallerano J, Cavicchi R, Ganda O, Hamdy O, Kirby R, Murtha T, Schlossman D, Shah S, Sharuk G, Silva P, Silver P, Stockman M, Sun J, Weimann E, Wolpert H, Aiello L, Jacobson A, Rand L, Rosenzwieg J, Nathan D, Larkin M, Christofi M, Folino K, Godine J, Lou P, Stevens C, Anderson E, Bode H, Brink S, Cornish C, Cros D, Delahanty L, eManbey ., Haggan C, Lynch J, McKitrick C, Norman D, Moore D, Ong M, Taylor C, Zimbler D, Crowell S, Fritz S, Hansen K, Gauthier‐Kelly C, Service F, Ziegler G, Barkmeier A, Schmidt L, French B, Woodwick R, Rizza R, Schwenk W, Haymond M, Pach J, Mortenson J, Zimmerman B, Lucas A, Colligan R, Luttrell L, Lopes‐Virella M, Caulder S, Pittman C, Patel N, Lee K, Nutaitis M, Fernandes J, Hermayer K, Kwon S, Blevins A, Parker J, Colwell J, Lee D, Soule J, Lindsey P, Bracey M, Farr A, Elsing S, Thompson T, Selby J, Lyons T, Yacoub‐Wasef S, Szpiech M, Wood D, Mayfield R, Molitch M, Adelman D, Colson S, Jampol L, Lyon A, Gill M, Strugula Z, Kaminski L, Mirza R, Simjanoski E, Ryan D, Johnson C, Wallia A, Ajroud‐Driss S, Astelford P, Leloudes N, Degillio A, Schaefer B, Mudaliar S, Lorenzi G, Goldbaum M, Jones K, Prince M, Swenson M, Grant I, Reed R, Lyon R, Kolterman O, Giotta M, Clark T, Friedenberg G, Sivitz W, Vittetoe B, Kramer J, Bayless M, Zeitler R, Schrott H, Olson N, Snetselaar L, Hoffman R, MacIndoe J, Weingeist T, Fountain C, Miller R, Johnsonbaugh S, Patronas M, Carney M, Mendley S, Salemi P, Liss R, Hebdon M, Counts D, Donner T, Gordon J, Hemady R, Kowarski A, Ostrowski D, Steidl S, Jones B, Herman W, Martin C, Pop‐Busui R, Greene D, Stevens M, Burkhart N, Sandford T, Floyd J, Bantle J, Flaherty N, Terry J, Koozekanani D, Montezuma S, Wimmergren N, Rogness B, Mech M, Strand T, Olson J, McKenzie L, Kwong C, Goetz F, Warhol R, Hainsworth D, Goldstein D, Hitt S, Giangiacomo J, Schade D, Canady J, Burge M, Das A, Avery R, Ketai L, Chapin J, Schluter M, Rich J, Johannes C, Hornbeck D, Schutta M, Bourne P, Brucker A, Braunstein S, Schwartz S, Maschak‐Carey B, Baker L, Orchard T, Cimino L, Songer T, Doft B, Olson S, Becker D, Rubinstein D, Bergren R, Fruit J, Hyre R, Palmer C, Silvers N, Lobes L, Rath PP, Conrad P, Yalamanchi S, Wesche J, Bratkowksi M, Arslanian S, Rinkoff J, Warnicki J, Curtin D, Steinberg D, Vagstad G, Harris R, Steranchak L, Arch J, Kelly K, Ostrosaka P, Guiliani M, Good M, Williams T, Olsen K, Campbell A, Shipe C, Conwit R, Finegold D, Zaucha M, Drash A, Morrison A, Malone J, Bernal M, Pavan P, Grove N, Tanaka E, McMillan D, Vaccaro‐Kish J, Babbione L, Solc H, DeClue T, Dagogo‐Jack S, Wigley C, Ricks H, Kitabchi A, Chaum E, Murphy M, Moser S, Meyer D, Iannacone A, Yoser S, Bryer‐Ash M, Schussler S, Lambeth H, Raskin P, Strowig S, Basco M, Cercone S, Zinman B, Barnie A, Devenyi R, Mandelcorn M, Brent M, Rogers S, Gordon A, Bakshi N, Perkins B, Tuason L, Perdikaris F, Ehrlich R, Daneman D, Perlman K, Ferguson S, Palmer J, Fahlstrom R, de Boer I, Kinyoun J, Van Ottingham L, Catton S, Ginsberg J, McDonald C, Harth J, Driscoll M, Sheidow T, Mahon J, Canny C, Nicolle D, Colby P, Dupre J, Hramiak I, Rodger N, Jenner M, Smith T, Brown W, May M, Lipps Hagan J, Agarwal A, Adkins T, Lorenz R, Feman S, Survant L, White N, Levandoski L, Grand G, Thomas M, Joseph D, Blinder K, Shah G, Burgess D, Boniuk I, Santiago J, Tamborlane W, Gatcomb P, Stoessel K, Ramos P, Fong K, Ossorio P, Ahern J, Gubitosi‐Klug R, Meadema‐Mayer L, Beck C, Farrell K, Genuth S, Quin J, Gaston P, Palmert M, Trail R, Dahms W, Lachin J, Backlund J, Bebu I, Braffett B, Diminick L, Gao X, Hsu W, Klumpp K, Pan H, Trapani V, Cleary P, McGee P, Sun W, Villavicencio S, Anderson K, Dews L, Younes N, Rutledge B, Chan K, Rosenberg D, Petty B, Determan A, Kenny D, Williams C, Cowie C, Siebert C, Steffes M, Arends V, Bucksa J, Nowicki M, Chavers B, O'Leary D, Polak J, Harrington A, Funk L, Crow R, Gloeb B, Thomas S, O'Donnell C, Soliman E, Zhang Z, Li Y, Campbell C, Keasler L, Hensley S, Hu J, Barr M, Taylor T, Prineas R, Feldman E, Albers J, Low P, Sommer C, Nickander K, Speigelberg T, Pfiefer M, Schumer M, Moran M, Farquhar J, Ryan C, Sandstrom D, Williams T, Geckle M, Cupelli E, Thoma F, Burzuk B, Woodfill T, Danis R, Blodi B, Lawrence D, Wabers H, Gangaputra S, Neill S, Burger M, Dingledine J, Gama V, Sussman R, Davis M, Hubbard L, Budoff M, Darabian S, Rezaeian P, Wong N, Fox M, Oudiz R, Kim L, Detrano R, Cruickshanks K, Dalton D, Bainbridge K, Lima J, Bluemke D, Turkbey E, der Geest ., Liu C, Malayeri A, Jain A, Miao C, Chahal H, Jarboe R, Nathan D, Monnier V, Sell D, Strauch C, Hazen S, Pratt A, Tang W, Brunzell J, Purnell J, Natarajan R, Miao F, Zhang L, Chen Z, Paterson A, Boright A, Bull S, Sun L, Scherer S, Lopes‐Virella M, Lyons T, Jenkins A, Klein R, Virella G, Jaffa A, Carter R, Stoner J, Garvey W, Lackland D, Brabham M, McGee D, Zheng D, Mayfield R, Maynard J, Wessells H, Sarma A, Jacobson A, Dunn R, Holt S, Hotaling J, Kim C, Clemens Q, Brown J, McVary K. Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. J Am Heart Assoc 2018. [PMCID: PMC6015340 DOI: 10.1161/jaha.117.008368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background
Hyperglycemia leading to increased oxidative stress is implicated in the increased risk for the development of macrovascular and microvascular complications in patients with type 1 diabetes mellitus.
Methods and Results
A random subcohort of 349 participants was selected from the
DCCT
/
EDIC
(Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications) cohort. This included 320 controls and 29 cardiovascular disease cases that were augmented with 98 additional known cases to yield a case cohort of 447 participants (320 controls, 127 cases). Biosamples from
DCCT
baseline, year 1, and closeout of
DCCT
, and 1 to 2 years post‐
DCCT
(
EDIC
years 1 and 2) were measured for markers of oxidative stress, including plasma myeloperoxidase, paraoxonase activity, urinary F
2α
isoprostanes, and its metabolite, 2,3 dinor‐8
iso
prostaglandin F
2α
. Following adjustment for glycated hemoblobin and weighting the observations inversely proportional to the sampling selection probabilities, higher paraoxonase activity, reflective of antioxidant activity, and 2,3 dinor‐8
iso
prostaglandin F
2α
, an oxidative marker, were significantly associated with lower risk of cardiovascular disease (−4.5% risk for 10% higher paraoxonase,
P
<0.003; −5.3% risk for 10% higher 2,3 dinor‐8
iso
prostaglandin F
2α
,
P
=0.0092). In contrast, the oxidative markers myeloperoxidase and F
2α
isoprostanes were not significantly associated with cardiovascular disease after adjustment for glycated hemoblobin. There were no significant differences between
DCCT
intensive and conventional treatment groups in the change in all biomarkers across time segments.
Conclusions
Heightened antioxidant activity (rather than diminished oxidative stress markers) is associated with lower cardiovascular disease risk in type 1 diabetes mellitus, but these biomarkers did not change over time with intensification of glycemic control.
Clinical Trial Registration
URL
:
https://www.clinicaltrials.gov
. Unique identifiers:
NCT
00360815 and
NCT
00360893.
Collapse
Affiliation(s)
- W.H. Wilson Tang
- Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
- Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
| | - Paula McGee
- The Biostatistics Center, George Washington University, Rockville, MD
| | - John M. Lachin
- The Biostatistics Center, George Washington University, Rockville, MD
| | - Daniel Y. Li
- Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
| | | | - Stanley L. Hazen
- Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
- Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Duchet C, Moraru GM, Segev O, Spencer M, Hayoon AG, Blaustein L. Effects of flash flooding on mosquito and community dynamics in experimental pools. J Vector Ecol 2017; 42:254-263. [PMID: 29125248 DOI: 10.1111/jvec.12265] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Accepted: 06/12/2017] [Indexed: 06/07/2023]
Abstract
Pulsed disturbances of larval mosquito sites are likely to have a direct negative effect on mosquitoes but may also have indirect effects due to the alteration of community structure. These altered communities may become attractive to gravid mosquitoes searching for oviposition sites when the disturbances decrease the abundance of mosquito antagonists such as competitors, which often results in an increase in mosquito food resources. However, flash flood disturbances in intermittent riverbeds can also remove mosquito food resources such as algae, so that the net effect of flash floods could be either to increase or decrease mosquito abundance. We conducted an outdoor mesocosm experiment to assess the effects of flash floods on mosquito oviposition habitat selection and larval abundance during the post-disturbance period of community recovery. Mesocosms were artificially flooded. Mosquito oviposition, immature abundance, invertebrate species diversity, chlorophyll a, and abiotic parameters were monitored. Our results showed that the flash flood negatively affected phytoplankton and zooplankton, leading to a decrease of mosquito oviposition in flooded mesocosms compared to non-flooded mesocosms. More broadly, this study indicates how disturbances influence mosquito oviposition habitat selection due to the loss of food resources in ephemeral pools, and it highlights the importance of considering the effects of disturbances in management, habitat restoration, and biodiversity conservation in temporary aquatic habitats.
Collapse
Affiliation(s)
- C Duchet
- Community Ecology Laboratory, Institute of Evolution and Department of Evolutionary & Environmental Biology, Faculty of Natural Sciences, University of Haifa, Israel
- Current address: WSU Puyallup Research and Extension Center, Puyallup, WA 98371, U.S.A
| | - G M Moraru
- Community Ecology Laboratory, Institute of Evolution and Department of Evolutionary & Environmental Biology, Faculty of Natural Sciences, University of Haifa, Israel
| | - O Segev
- Community Ecology Laboratory, Institute of Evolution and Department of Evolutionary & Environmental Biology, Faculty of Natural Sciences, University of Haifa, Israel
| | - M Spencer
- School of Environmental Sciences, University of Liverpool, UK
| | - A Gershberg Hayoon
- Community Ecology Laboratory, Institute of Evolution and Department of Evolutionary & Environmental Biology, Faculty of Natural Sciences, University of Haifa, Israel
| | - L Blaustein
- Community Ecology Laboratory, Institute of Evolution and Department of Evolutionary & Environmental Biology, Faculty of Natural Sciences, University of Haifa, Israel
| |
Collapse
|
17
|
Young C, Mokhonova E, Quinonez M, Pyle A, Spencer M. Application of a CRISPR/Cas9 gene editing therapy in a novel humanized dystrophic mouse model of Duchenne muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Humphreys H, Becker K, Dohmen P, Petrosillo N, Spencer M, van Rijen M, Wechsler-Fördös A, Pujol M, Dubouix A, Garau J. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. J Hosp Infect 2016; 94:295-304. [DOI: 10.1016/j.jhin.2016.06.011] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 06/06/2016] [Indexed: 12/13/2022]
|
19
|
Young C, Hicks M, Ermolova N, Nakano H, Jan M, Younesi S, Nelson S, Miceli C, Pyle A, Spencer M. Development of a CRISPR/Cas9-mediated gene editing platform to restore the reading frame for 60% of Duchenne muscular dystrophy patients. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Huang CY, Zhou J, Tra VT, White R, Trappen R, N'Diaye AT, Spencer M, Frye C, Cabrera GB, Nguyen V, LeBeau JM, Chu YH, Holcomb MB. Imaging magnetic and ferroelectric domains and interfacial spins in magnetoelectric La0.7Sr0.3MnO3/PbZr0.2Ti0.8O3 heterostructures. J Phys Condens Matter 2015; 27:504003. [PMID: 26613406 DOI: 10.1088/0953-8984/27/50/504003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Strong magnetoelectric coupling can occur at the interface between ferromagnetic and ferroelectric films. Similar to work on interfacial exchange bias, photoemission electron microscopy was utilized to image both magnetic and ferroelectric domains and the resulting interfacial Ti spin in the same locations of La0.7Sr0.3MnO3/PbZr0.2Ti0.8O3 heterostructures. Multiple image analysis techniques, which could be applicable for a variety of fields needing quantitative data on image switching, confirm both improved magnetic switching and an increased population of interfacial spins with increased thickness of the ultrathin La0.7Sr0.3MnO3 layer. The perpendicular orientation of the interfacial spins is also discussed. This work suggests a magnetoelectric dead layer, with reduced interfacial magnetoelectricity when thin magnetic films are present.
Collapse
Affiliation(s)
- C-Y Huang
- Department of Physics and Astronomy, West Virginia University, Morgantown, WV 26506, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Stadheim HK, Nossum EM, Olsen R, Spencer M, Jensen J. Caffeine improves performance in double poling during acute exposure to 2,000-m altitude. J Appl Physiol (1985) 2015; 119:1501-9. [DOI: 10.1152/japplphysiol.00509.2015] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 10/06/2015] [Indexed: 11/22/2022] Open
Abstract
There is limited research on the physiological effects of caffeine (CAF) ingestion on exercise performance during acute hypoxia. The aim of the present study was therefore to test the effect of placebo (PLA) and CAF (4.5 mg/kg) on double poling (DP) performance during acute hypoxia. Thirteen male subelite cross-country skiers (V̇o2max 72.6 ± 5.68 ml·kg−1·min−1) were included. Performance was assessed as 1) an 8-km cross-country DP time-trial (C-PT), and 2) time until task failure at a set workload equal to ∼90% of DP V̇o2max. Testing was carried out in a hypobaric chamber, at 800 mbar (Pio2: ∼125 mmHg) corresponding to ∼2,000 m above sea level in a randomized double-blinded, placebo-controlled, cross-over design. CAF improved time to task failure from 6.10 ± 1.40 to 7.22 ± 1.30 min ( P < 0.05) and velocity the first 4 km ( P < 0.05) but not overall time usage for the 8-km C-PT. During submaximal exercise subjects reported lower pain in arms and rate of perceived exertion (RPE) following CAF ingestion. Throughout C-PTs similar RPE and pain was shown between treatments. However, higher heart rate was observed during the CAF 8 km (187 ± 7 vs. 185 ± 7; P < 0.05) and 90% C-PT (185 ± 7 vs. 181 ± 9) associated with increased ventilation, blood lactate, glucose, adrenaline, decreased pH, and bicarbonate. The present study demonstrates for the first time that CAF ingestion improves DP time to task failure although not consistently time trial performance during acute exposure to altitude. Mechanisms underpinning improvements seem related to reduced pain RPE and increased heart rate during CAF C-PTs.
Collapse
Affiliation(s)
- H. K. Stadheim
- Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway; and
| | - E. M Nossum
- Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway; and
| | - R. Olsen
- Department of Chemical and Biological Working Environment, National Institute of Occupational Health, Oslo, Norway
| | - M. Spencer
- Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway; and
| | - J. Jensen
- Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway; and
| |
Collapse
|
22
|
Mitchell A, Spencer M, Edmiston C. Role of healthcare apparel and other healthcare textiles in the transmission of pathogens: a review of the literature. J Hosp Infect 2015; 90:285-92. [PMID: 25935701 PMCID: PMC7132459 DOI: 10.1016/j.jhin.2015.02.017] [Citation(s) in RCA: 130] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 02/25/2015] [Indexed: 11/13/2022]
Abstract
Healthcare workers (HCWs) wear uniforms, such as scrubs and lab coats, for several reasons: (1) to identify themselves as hospital personnel to their patients and employers; (2) to display professionalism; and (3) to provide barrier protection for street clothes from unexpected exposures during the work shift. A growing body of evidence suggests that HCWs' apparel is often contaminated with micro-organisms or pathogens that can cause infections or illnesses. While the majority of scrubs and lab coats are still made of the same traditional textiles used to make street clothes, new evidence suggests that current innovative textiles function as an engineering control, minimizing the acquisition, retention and transmission of infectious pathogens by reducing the levels of bioburden and microbial sustainability. This paper summarizes recent literature on the role of apparel worn in healthcare settings in the acquisition and transmission of healthcare-associated pathogens. It proposes solutions or technological interventions that can reduce the risk of transmission of micro-organisms that are associated with the healthcare environment. Healthcare apparel is the emerging frontier in epidemiologically important environmental surfaces.
Collapse
Affiliation(s)
- A Mitchell
- International Safety Center, The Public's Health, Apopka, FL, USA.
| | - M Spencer
- Infection Preventionist Consultants, Boston, MA, USA
| | - C Edmiston
- Department of Surgery, Surgical Microbiology and Hospital Epidemiology Research Laboratory, Medical College of Wisconsin, Milwaukee, WI, USA
| |
Collapse
|
23
|
Lisiecka D, Holt R, Tait R, Ford M, Lai M, Chura L, Baron-Cohen S, Spencer M, Suckling J. Alterations in White Matter Development in Adolescents with Autistic Spectrum Conditions and Their Siblings. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30957-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
24
|
Diels J, Hamberg P, Ford D, Price PW, Spencer M, Dass RN. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res 2014; 24:591-8. [PMID: 25326871 PMCID: PMC4349944 DOI: 10.1007/s11136-014-0794-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/19/2014] [Indexed: 11/23/2022]
Abstract
Purpose To construct a model to predict preference-adjusted EuroQol 5D (EQ-5D) health utilities for patients with metastatic castrate-resistant prostate cancer (mCRPC) using the disease-specific health-related quality of life (HRQoL) measure, functional assessment of cancer therapy-prostate (FACT-P). Methods HRQoL data were collected from patients with mCRPC who were enrolled in an observational study conducted in 47 centers across six European Union countries. Utility values were generated using a UK-specific EQ-5D value set. The predictive validity of the five FACT-P subscales, patient demographics, comorbidities and prior chemotherapy was tested using ordinary least squares (OLS), median, Gamma and Tobit multivariate regression models. Results FACT-P and EQ-5D questionnaires were completed by 602 (86 %) patients. Mean age [standard deviation (SD)] was 72.1 (7.9) years, mean time from diagnosis (SD) was 5.4 (4.4) years, and mean time since failure of androgen deprivation therapy (SD) was 1.0 (1.6) years. At study inclusion, 39 % of patients were chemotherapy-naïve, 37 % were undergoing chemotherapy, and 24 % were post-chemotherapy. Mean FACT-P and EQ-5D utility values were 104 and 0.66, respectively. OLS regression was the best-performing model, explaining 61.2 % of the observed EQ-5D variation. All FACT-P subscales were significantly predictive; the physical and functional well-being subscales had the highest explanatory value (coefficient 0.023 and 0.001, respectively, p < 0.0001). The other variables did not add additional explanatory value. Conclusions The algorithm developed enables translation of cancer-specific HRQoL measures to preference-adjusted health status in patients with mCRPC. The function may be useful in calculating EQ-5D scores when EQ-5D data have not been gathered directly.
Collapse
Affiliation(s)
- J Diels
- Janssen Pharmaceutica NV, Beerse, Belgium,
| | | | | | | | | | | |
Collapse
|
25
|
Greenbaum A, Chaves SS, Perez A, Aragon D, Bandyopadhyay A, Bennett N, Fowler B, Hancock E, Lynfield R, McDonald-Hamm C, Reingold A, Ryan P, Schaffner W, Sharangpani R, Spencer M, Thomas A, Yousey-Hindes K, Zansky S, Finelli L. Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012. Infection 2013; 42:165-70. [DOI: 10.1007/s15010-013-0534-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 09/10/2013] [Indexed: 11/25/2022]
|
26
|
Pestian J, Matykiewicz P, Holland-Bouley K, Standridge S, Spencer M, Glauser T. Selecting anti-epileptic drugs: a pediatric epileptologist's view, a computer's view. Acta Neurol Scand 2013; 127:208-15. [PMID: 22998126 DOI: 10.1111/ane.12002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/25/2012] [Indexed: 01/13/2023]
Abstract
OBJECTIVE To identify which clinical characteristics are important to include in clinical decision support systems developed for Antiepileptic Drug (AEDs) selection. METHODS Twenty-three epileptologists from the Childhood Absence Epilepsy network completed a survey related to AED selection. Using cluster analysis their responses where classified into subject matter groups and weighted for importance. RESULTS Five distinct subject matter groups were identified and their relative weighting for importance were determined: disease characteristics (weight 4.8 ± 0.049), drug toxicities (3.82 ± 0.098), medical history (3.12 ± 0.102), systemic characteristics (2.57 ± 0.048) and genetic characteristics (1.08 ± 0.046). CONCLUSION Research about prescribing patterns exists but research on how such data can be used to train advanced technology is novel. As machine learning algorithms becomes more and more prevalent in clinical decisions support systems, developing methods for determining which data should be part of those algorithms is equally important.
Collapse
Affiliation(s)
- J. Pestian
- Division of Biomedical Informatics; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| | - P. Matykiewicz
- Division of Biomedical Informatics; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| | - K. Holland-Bouley
- Division of Pediatric Neurology; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| | - S. Standridge
- Division of Pediatric Neurology; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| | - M. Spencer
- Division of Biomedical Informatics; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| | - T. Glauser
- Division of Pediatric Neurology; Cincinnati Children's Hospital Medical Center; Cincinnati; OH; USA
| |
Collapse
|
27
|
Dass R, Hamberg P, Spencer M, Price PW. Quality of Life of Patients with Metastatic Castration-Resistant Prostate Cancer: Results from An Observational Study in 6 European Countries. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33516-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
28
|
Besterman EM, Spencer M. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol 2012; 8 Suppl 2:205S-9S. [DOI: 10.1111/j.1365-2125.1979.tb04782.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
29
|
Bower MA, Whitten M, Nisbet RER, Spencer M, Dominy KM, Murphy AM, Cassidy R, Barrett E, Hill EW, Binns M. Thoroughbred racehorse mitochondrial DNA demonstrates closer than expected links between maternal genetic history and pedigree records. J Anim Breed Genet 2012; 130:227-35. [PMID: 23679948 DOI: 10.1111/j.1439-0388.2012.01018.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Accepted: 06/16/2012] [Indexed: 11/27/2022]
Abstract
The potential future earnings and therefore value of Thoroughbred foals untested in the racing arena are calculated based on the performance of their forebears. Thus, lineage is of key importance. However, previous research indicates that maternally inherited mitochondrial DNA (mtDNA) does not correspond to maternal lineage according to recorded pedigree, casting doubt on the voracity of historic pedigrees. We analysed mtDNA of 296 Thoroughbred horses from 33 maternal lineages and identified an interesting trend. Subsequent to the founding of the Thoroughbred breed in the 16th century, well-populated maternal lineages were divided into sub-lineages. Only six in 10 of the Thoroughbreds sampled shared mitochondrial haplotype with other members of their maternal lineage, despite having a common maternal ancestor according to pedigree records. However, nine in 10 Thoroughbreds from the 103 sub-lineages sampled shared mtDNA with horses of their maternal pedigree sub-lineage. Thus, Thoroughbred maternal sub-lineage pedigree represents a more accurate breeding record than previously thought. Errors in pedigrees must have occurred largely, though, not exclusively, at sub-lineage foundation events, probably due to incomplete understanding of modes of inheritance in the past, where maternal sub-lineages were founded from individuals, related, but not by female descent.
Collapse
Affiliation(s)
- M A Bower
- McDonald Institute for Archaeological Research, University of Cambridge, Cambridge, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Steele A, McCubbin FM, Fries M, Kater L, Boctor NZ, Fogel ML, Conrad PG, Glamoclija M, Spencer M, Morrow AL, Hammond MR, Zare RN, Vicenzi EP, Siljestrom S, Bowden R, Herd CDK, Mysen BO, Shirey SB, Amundsen HEF, Treiman AH, Bullock ES, Jull AJT. A Reduced Organic Carbon Component in Martian Basalts. Science 2012; 337:212-5. [DOI: 10.1126/science.1220715] [Citation(s) in RCA: 155] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
31
|
|
32
|
Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, Lang RA, Hegde RS. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 2010; 29:3715-22. [PMID: 20418914 DOI: 10.1038/onc.2010.122] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The Eyes Absent (EYA) proteins combine transactivation, tyrosine phosphatase, and threonine phosphatase activities in their function as part of a conserved regulatory cascade involved in embryonic organ development. EYA tyrosine phosphatase activity contributes to fly eye development, and vertebrate EYA is involved in promoting DNA damage repair subsequent to genotoxic stress. EYAs are known to be expressed at elevated levels in ovarian and breast cancers. Here, we show that the tyrosine phosphatase activity of the EYAs promotes tumor cell migration, invasion, and transformation. These cellular effects are accompanied by alterations of the actin cytoskeleton and increased levels of active Rac and Cdc42. The invasiveness conferred by EYA is reflected in vivo by inhibition of metastasis seen when EYA3 expression is silenced in the invasive breast cancer cell line MDA-MB-231. Together, our data directly associate the tyrosine phosphatase activity of the EYAs with the oncogenesis-associated cellular properties of motility and invasiveness.
Collapse
Affiliation(s)
- R N Pandey
- Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Jadwisienczak W, Wisniewski K, Spencer M, Thomas T, Ingram D. Optical properties, luminescence quenching mechanism and radiation hardness of Eu-doped GaN red powder phosphor. RADIAT MEAS 2010. [DOI: 10.1016/j.radmeas.2009.12.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, Vestbo J. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2009; 35:532-9. [DOI: 10.1183/09031936.00153108] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
36
|
|
37
|
Abd El-Mohsen M, Spencer M, Ehsan N, Hussein A, Hammouda F, Hifnawy M, Ismail S. Antioxidant and hepatoprotective activities of terpenoids isolated from Salvia multicaulis Vahl. Planta Med 2009; 75. [DOI: 10.1055/s-0029-1234535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
38
|
|
39
|
Spencer M. Medico-legal aspects of delay in breast cancer diagnosis: the legal perspective. Breast Cancer Res 2006. [PMCID: PMC3332678 DOI: 10.1186/bcr1440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
|
41
|
Spencer M, Rechichi C, Lawrence S, Dawson B, Bishop D, Goodman C. Time-motion analysis of elite field hockey during several games in succession: a tournament scenario. J Sci Med Sport 2006; 8:382-91. [PMID: 16602166 DOI: 10.1016/s1440-2440(05)80053-2] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
International field hockey tournaments may require teams to play three games within a period of four days. Therefore, there is potential for residual fatigue to affect the movement patterns of players during subsequent games. The purpose of this study was to document changes in time-motion analysis of 14 elite male field hockey players during three games within a period of four days during an international tournament. In addition, the nature of and any changes in repeated-sprint activity were investigated using a criteria of a minimum of three sprints with a mean recovery duration between sprints of < 21 s. The percent of total game time spent standing significantly increased across all three games (7.4+/-.2, 11.2+/-2.7 and 15.6+/-5.6%, respectively, P<0.05). Conversely, the percent time spent jogging significantly decreased from game 1 to game 2 and from game 1 to game 3 (40.5+/-7.3, 34.8+/-7.4 and 29.4+/-5.7%, respectively, P<0.05). Furthermore, the percent time in striding significantly increased from game 1 to game 3 and from game 2 to game 3 (4.1+/-1.3, 5.1+/-0.9 and 5.8+/-1.4%, respectively. P<0.05). Changes in mean motion frequency and duration were recorded across games for the motions of standing, striding and sprinting. The frequency of exercise bouts that met the criteria for 'repeated-sprint' decreased across the three games (17, 11 and 8, respectively). In summary, the results suggest that when elite field hockey players play three games within four days there are significant changes in time-motion analysis.
Collapse
Affiliation(s)
- M Spencer
- Team Sport Research Group, School of Human Movement and Exercise Science, The University of Western Australia, Crawley.
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
The purpose of this study was to assess the reliability of a repeated-sprint test, specifically designed for field-hockey, as it was based directly on the time-motion analysis of elite level competition. The test consisted of 6 x 30-m over-ground sprints departing on 25s, with an active recovery (approximately 3.1-3.3 ms(-1)) between sprints. Ten highly trained, male, field-hockey players (mean+/-S.D.: age, 23+/-3 years; body mass, 78.1+/-7.1 kg) participated in this study. Following familiarisation, the subjects performed the repeated-sprint test on two occasions, 7 days apart. The reliability of the test variables was assessed by the typical error of measurement (TE). The total sprint time was very reliable (T(1): 26.79+/-0.76 s versus T2: 26.83+/-0.74 s), as the TE was 0.7% (95% CL, 0.5-1.2%). However, the percent sprint decrement was less reliable (T1: 5.6+/-0.9% versus T2: 5.8+/-1.0%), with the TE being 14.9% (95% CL, 10.8-31.3%). In summary, it is suggested that this field-hockey-specific, repeated-sprint test is very reliable when the results are presented as the total sprint time.
Collapse
Affiliation(s)
- M Spencer
- Team Sport Research Group, School of Human Movement and Exercise Science, The University of Western Australia, Crawley, WA 6009, Australia.
| | | | | | | | | |
Collapse
|
43
|
Spencer M, Hoikala K, Gulcyzinski D. The “Don't Catch the Flu Bear Blues” educational campaign to increase hand hygiene awareness during the flu vaccine shortage in an orthopedic specialty hospital. Am J Infect Control 2005. [DOI: 10.1016/j.ajic.2005.04.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Spencer M, Gulcyzinski D, Dejoie P, Davidson S. Surgical site surveillance and standardized infection ratios in an orthopedic specialty hospital. Am J Infect Control 2005. [DOI: 10.1016/j.ajic.2005.04.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Spencer M, Anderson P, Creamer A. The E=MC2 project: Environment=maintaining cleanliness, a multidisciplinary approach to establish a routine cleaning schedule for medical equipment. Am J Infect Control 2005. [DOI: 10.1016/j.ajic.2005.04.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Martínez A, Brethauer U, Rojas IG, Spencer M, Mucientes F, Borlando J, Rudolph MI. Expression of apoptotic and cell proliferation regulatory proteins in actinic cheilitis. J Oral Pathol Med 2005; 34:257-62. [PMID: 15817067 DOI: 10.1111/j.1600-0714.2004.00299.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Actinic cheilitis (AC) is a pre-malignant lesion caused by ultraviolet (UV) radiation. The apoptotic proteins p53, bax, bcl-2, and the proliferation marker Ki-67, are known to play an important role in UV-exposed skin and carcinomas, therefore, these markers were assessed in AC and compared with normal lip and oral mucosa. METHODS AC (n = 13), normal lip (n = 7) and oral mucosa (n = 6) biopsies were stained immunohistochemically for p53, bax, bcl-2 and Ki-67, to determine their expression and distribution. RESULTS p53 was over-expressed in AC as compared with normal lip and oral mucosa (P < 0.003). Although bcl-2 expression was higher in AC than in oral mucosa (P < 0.002), it was significantly reduced as compared with normal lip (P < 0.04). Bax expression remained unchanged, and Ki-67 was significantly increased in AC and normal lip as compared with oral mucosa (P < 0.05). CONCLUSION The results suggest that DNA-damaged cells by UV radiation in AC are eliminated by apoptosis.
Collapse
Affiliation(s)
- A Martínez
- Department of Oral Pathology, College of Dentistry, Universidad de Concepción, Chile.
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Repeated-sprint ability is thought to be an important fitness component of team sports. However, little is known about the effect sport-specific training has on this fitness component. Therefore, the purpose of this study was to investigate the effects of field-hockey specific training on repeated-sprint ability, plasma hypoxanthine (Hx) concentration and other blood parameters in 18 elite female field-hockey players. All subjects performed a repeated-sprint ability test on a cycle ergometer (5 x 6-sec maximal sprints every 30 secs) before and after seven weeks of training, designed to improve repeated-sprint ability. Following training, there was a significant (P< 0.05) increase in absolute total work (20.73+/-2.00 to 21.15+/-2.07 kJ, mean+/-SD). However, there was no significant change in total work when expressed per kg of body mass (341.3+/-16.4 to 345.5+/-18.8 J x kg(-1)). In addition, training resulted in a significant (P< 0.05) decrease in change values (peak-rest values) for Hx (8.2+/-3.8 to 5.5+/-2.7 micromol x L(-1)) and hydrogen ion concentration (22.8+/-5.2 to 19.1+/-5.1 nmol x L(-1)). The significant increase in absolute total work following seven weeks of field-hockey specific training was most likely due to an increase in lean muscle mass. The significant decrease in plasma Hx concentration (post-test minus rest values) following seven weeks of field hockey-specific training provides evidence that Hx production and/or efflux from the muscle are reduced. Therefore, one adaptation of sport-specific repeated-sprint training may be to conserve the purine nucleotide pool.
Collapse
Affiliation(s)
- M Spencer
- Team Sport Research Centre Group, School of Human Movement and Exercise Science, The University of Western Australia, Crawley, Western Australia, Australia
| | | | | |
Collapse
|
48
|
Bishop D, Spencer M. Determinants of repeated-sprint ability in well-trained team-sport athletes and endurance-trained athletes. J Sports Med Phys Fitness 2004; 44:1-7. [PMID: 15181383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
AIM To examine the importance of peak .VO(2) in determining repeated-sprint ability (RSA), we recruited 20 well-trained females (10 team-sport athletes and 10 endurance-trained runners; mean SD peak .VO(2): 3.3+/-0.2 L x min(-1)) who were homogenous with respect to peak .VO(2) (mean difference = 0.05 L x min(-1)). METHODS Tests consisted of a RSA cycle test (5 x 6-s max sprints every 30 s) and a peak .VO(2) test. Venous and capillary blood was sampled immediately before and after the 5 x 6-s cycle test for the determination of hypoxanthine concentration ([Hx]), lactate concentration ([La-]) and pH; blood buffer capacity (beta(blood)) was also estimated. RESULTS The team-sport athletes had significantly higher peak power for the 1(st) sprint (P(1); W x kg(-1)), total work for 5 x 6-s sprints (W(tot); J x kg(-1)) and power decrement across the 5 sprints (P(dec)), (p<0.05). There were also significant between-group differences for post-test values of [Hx], [La-] and pH (p<0.05). While there was no significant difference in beta(blood) between the 2 groups (p=0.10), there was a moderate effect (d=0.77). CONCLUSION These results suggest that factors in addition to peak .VO(2) are likely to be important for RSA.
Collapse
Affiliation(s)
- D Bishop
- School of Human Movement and Exercise Science, University of Western Australia, Crawley, WA, Australia.
| | | |
Collapse
|
49
|
Abstract
Fluoride is added to many dental restorative materials, including glass-ionomer cements, for the specific purpose of leaching fluoride into the surrounding tissues to provide secondary caries inhibition. During the caries process, an acidic environment attacks the dental tissues as well as the glass-ionomer cement. We hypothesized that pH significantly affects the rate of release of fluoride from the glass-ionomer cement. A continuous-flow fluoride-measuring system that monitors the amount of fluoride released over time was used to determine the release of fluoride from a resin-modified glass-ionomer cement (KetacFil). The results show that the release rate began with a fast burst of fluoride which quickly diminished to low levels in 3 days. Under neutral pH conditions, the rate of fluoride release at 72 hrs was significantly slower than at pH 4.
Collapse
Affiliation(s)
- C M Carey
- Paffenbarger Research Center, American Dental Association Foundation, National Institute of Standards and Technology, 100 Bureau Drive, Mail Stop 8546, Gaithersburg, MD 20899-8546, USA.
| | | | | | | |
Collapse
|
50
|
Abstract
SUMMARY Maynard Smith's maximum chi(2) method is a useful tool for detecting recombination. Significance testing is usually carried out by random permutation, which may require a large amount of computer time. I describe an exact algorithm. AVAILABILITY Matlab source code from http://www.bioc.cam.ac.uk/UTOs/howe/
Collapse
Affiliation(s)
- M Spencer
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, England.
| |
Collapse
|